Be the first to like.

Share

Healing spinal-cord injuries has been one of the most difficult — and doggedly pursued — quests in medicine, and among the most symbolic goals for the field of stem cells and regenerative medicine.

Progress, however, has been frustratingly slow. Dozens of seemingly promising efforts, based on animal studies, have fallen flat.

Last week, a Californian company called Asterias Biotherapeutics released promising results from a 12-month first phase clinical trial, in which embryonic stem cells are converted into oligodendrocytes — cells of the central nervous system that support neurons and can stimulate their growth — and then injected into the backs of people with a spinal-cord injury. The data show that injected cells do stick around at the injury site, and that most patients (21 out of 22) showed improved movement.

…continue reading ‘Editorial: Japan Should Put the Brakes on Stem-Cell Sales’

Image via Flickr AttributionNoncommercial Some rights reserved by National Institutes of Health (NIH)

Be the first to like.

Share
Nature

Tags: , , , , , , , , , , , , , ,

Leave a Reply